KLOW Blend 80mg GHK-Cu, TB-500, BPC-157, KPV KLOW Blend KLOW 80mg Peptide Blend (Lyophilized Powder) For Research Use Only GHK-Cu TB-500 BPC-157 KPV KLOW is an advanced 4-in-1 research peptide blend combining 80mg of compounds studied for their potential in tissue repair signaling, immune modulation, and cellular recovery mechanisms in controlled laboratory environments
It remains an investigational peptide, not an approved pharmaceutical
Hypoxia impedes OXPHOS by decreasing the influx of metabolites into the TCA cycle via the activation of pyruvate dehydrogenase kinase 1 (PDK1) in a HIF-1-dependent manner [40]
In September 2023, the FDA placed it in Category 2 of its interim 503A bulks list: the list of substances flagged for significant safety concerns that could not be used by compounding pharmacies
The cold temperature reduces the rate of any potential degradation, extending its shelf life significantly